AB Science receives US notice of allowance for masitinib patent in mCRPC

The USPTO issued a Notice of Allowance for a patent application covering use of masitinib to treat metastatic castrate resistant prostate cancer, AB Science announced. The company says the patent, once granted, would provide US protection until May 2042 and adds to existing European coverage.

The United States Patent and Trademark Office issued a Notice of Allowance for a patent application covering the use of masitinib to treat metastatic castrate resistant prostate cancer (mCRPC), AB Science announced. A Notice of Allowance indicates the USPTO intends to grant the application after completing certain formal procedural steps. AB Science states that, once granted, the patent would provide intellectual property protection in the United States until May 2042. This decision is presented as adding to related patent coverage already granted in Europe. Key points: - The USPTO issued a Notice of Allowance for patent application US 18/040884 for methods of treating mCRPC with masitinib, according to the company announcement. - AB Science says the granted US patent would extend protection until May 2042 and complements an existing European patent (EP4175639); counterpart applications have been filed in other markets. - A Notice of Allowance signals the USPTO's intent to grant after required formal procedural steps; the announcement did not specify a final grant date. Summary: The company reports the USPTO's decision strengthens its intellectual property position for masitinib in mCRPC in the United States through 2042 and aligns with prior European coverage. The NOA indicates the patent is expected to be granted after completion of formalities; final timing remains undetermined at this time.